---
title: "SEA STAR released its 2024 annual performance, turning from profit to a loss of 23.4075 million yuan"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/236814483.md"
description: "According to the Zhitong Finance APP, SEA STAR released its annual report for 2024. During the reporting period, the company achieved operating revenue of 595 million yuan, a year-on-year increase of 0.07%. The net loss attributable to shareholders of the listed company was 23.4075 million yuan. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 11.2258 million yuan. The basic loss per share was 0.0405 yuan"
datetime: "2025-04-21T14:27:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236814483.md)
  - [en](https://longbridge.com/en/news/236814483.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236814483.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/236814483.md) | [English](https://longbridge.com/en/news/236814483.md)


# SEA STAR released its 2024 annual performance, turning from profit to a loss of 23.4075 million yuan

According to the Zhitong Finance APP, SEA STAR (002137.SZ) released its annual report for 2024. During the reporting period, the company achieved operating revenue of 595 million yuan, a year-on-year increase of 0.07%. The net loss attributable to shareholders of the listed company was 23.4075 million yuan. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 11.2258 million yuan. The basic loss per share was 0.0405 yuan

### 相關股票

- [SEA STAR (002137.CN)](https://longbridge.com/zh-HK/quote/002137.CN.md)

## 相關資訊與研究

- [Kansas City International Airport reopens after brief closure due to unspecified threat](https://longbridge.com/zh-HK/news/278278269.md)
- [BYD reportedly explores F1 entry to boost global brand appeal](https://longbridge.com/zh-HK/news/278576491.md)
- [Junshi Biosciences’ Subcutaneous Toripalimab NDAs Accepted in China](https://longbridge.com/zh-HK/news/278445287.md)
- [Kainova reports positive top line results from Phase I EPRAD trial](https://longbridge.com/zh-HK/news/278702903.md)
- [Indel B Adds to Treasury Stock with New Share Buybacks on Euronext Milan](https://longbridge.com/zh-HK/news/278778618.md)